PMID- 10537336
OWN - NLM
STAT- MEDLINE
DCOM- 19991124
LR  - 20171116
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 5
IP  - 10
DP  - 1999 Oct
TI  - Selective in vivo mobilization with granulocyte macrophage colony-stimulating 
      factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell 
      progenitors from peripheral blood progenitor cells in patients with advanced 
      breast cancer undergoing autologous transplantation.
PG  - 2735-41
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that are essential for 
      the initiation of T cell-mediated immunity. DCs develop from myeloid progenitor 
      populations under the influence of granulocyte macrophage colony-stimulating 
      factor (GM-CSF) and pass through an intermediate stage of maturation that is 
      characterized by CD14 expression. Interest has focused on generating 
      human-derived DCs for antigen-specific tumor vaccines to be used as adjuvant 
      immunotherapy in minimal disease settings, such as after autologous 
      transplantation. In the present study, mobilized peripheral blood progenitor 
      cells (PBPCs) were obtained from 18 patients with locally advanced or metastatic 
      breast cancer preparing to undergo autologous stem cell transplantation. PBPCs 
      mobilized in 10 patients with GM-CSF for 1 week, followed by the combination of 
      GM-CSF and G-CSF, were compared with those obtained from patients receiving G-CSF 
      alone with respect to the presence of DC progenitors and the capacity to generate 
      functionally active mature DCs. PBPCs mobilized with GM-CSF/G-CSF were markedly 
      enriched for CD14+ DC progenitor cells as compared with those mobilized with 
      G-CSF alone. Consistent with an immature progenitor population, the CD14+ cells 
      express Ki-67 antigen but not nonspecific esterase. CD14+ cells purified by 
      fluorescence-activated cell sorting from PBPCs mobilized with either regimen and 
      cultured for 1 week in GM-CSF and interleukin-4 generated nearly pure populations 
      of cells with characteristic DC phenotype and function. The addition of GM-CSF to 
      the mobilization regimen resulted in greater yields of functionally active DCs 
      for potential use in posttransplant immunotherapy.
FAU - Avigan, D
AU  - Avigan D
AD  - Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, 
      Massachusetts 02215, USA. davigan@bidmc.harvard.edu
FAU - Wu, Z
AU  - Wu Z
FAU - Gong, J
AU  - Gong J
FAU - Joyce, R
AU  - Joyce R
FAU - Levine, J
AU  - Levine J
FAU - Elias, A
AU  - Elias A
FAU - Richardson, P
AU  - Richardson P
FAU - Milano, J
AU  - Milano J
FAU - Kennedy, L
AU  - Kennedy L
FAU - Anderson, K
AU  - Anderson K
FAU - Kufe, D
AU  - Kufe D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Breast Neoplasms/*therapy
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/*therapeutic use
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use
MH  - *Hematopoietic Stem Cell Mobilization
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunophenotyping
MH  - Interleukin-4/pharmacology
MH  - Lipopolysaccharide Receptors/analysis
MH  - Transplantation, Autologous
EDAT- 1999/10/28 00:00
MHDA- 1999/10/28 00:01
CRDT- 1999/10/28 00:00
PHST- 1999/10/28 00:00 [pubmed]
PHST- 1999/10/28 00:01 [medline]
PHST- 1999/10/28 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1999 Oct;5(10):2735-41.